Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Organicell Regenerative Medicine Inc (OCEL)
Organicell Regenerative Medicine Inc (OCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.06
Trade OCEL with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1200 +133.48%
on 02/07/24
3.5400 -26.13%
on 02/21/24
+1.1650 (+80.34%)
since 01/23/24
3-Month
0.8960 +191.85%
on 12/19/23
3.5400 -26.13%
on 02/21/24
+1.2150 (+86.79%)
since 11/22/23
52-Week
0.8960 +191.85%
on 12/19/23
4.8000 -45.52%
on 07/17/23
-0.3850 (-12.83%)
since 02/23/23

Most Recent Stories

More News
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID

/PRNewswire/ -- Research and development is still focused on trying to help understand the acute infection 9itself and the effects of long COVID as well. As...

OCEL : 2.6150 (-18.03%)
RGNX : 17.41 (-4.18%)
SBFM : 0.0525 (-12.65%)
ABBV : 178.09 (+0.76%)
RVNC : 5.49 (+3.39%)
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID

Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the...

SBFM : 0.0525 (-12.65%)
ABBV : 178.09 (+0.76%)
OCEL : 2.6150 (-18.03%)
RGNX : 17.41 (-4.18%)
RVNC : 5.49 (+3.39%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 47.32 (-2.05%)
OCEL : 2.6150 (-18.03%)
BRTX : 1.3700 (+4.58%)
MDXG : 8.20 (+0.24%)
NNVC : 1.3300 (+4.72%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

OCEL : 2.6150 (-18.03%)
BRTX : 1.3700 (+4.58%)
MDXG : 8.20 (+0.24%)
NNVC : 1.3300 (+4.72%)
VCEL : 47.32 (-2.05%)
BeautyHealth’s Hydrafacial Announces Partnership to Develop Breakthrough Exosome Booster

The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced a collaboration with biotech company Organicell to co-create a first-to-market exosome booster that will address...

SKIN : 2.93 (+2.81%)
OCEL : 2.6150 (-18.03%)
Organicell Announces Matt Sinnreich as CEO

MIAMI, FL / ACCESSWIRE / July 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological...

OCEL : 2.6150 (-18.03%)
Organicell Regenerative Medicine, Inc. Secures $4 Million in Funding for Clinical Trials and Agrees To Restructure Management

MIAMI, FL / ACCESSWIRE / July 20, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological...

OCEL : 2.6150 (-18.03%)
Organicell And Proxima CRO Set To Open Clinical Trial For Long Hauler COVID-19 Patients

MIAMI, FL / ACCESSWIRE / February 8, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced...

OCEL : 2.6150 (-18.03%)
Organicell Regenerative Medicine, Inc. Provides Updates of Clinical Trial Activities

MIAMI, FL / ACCESSWIRE / December 29, 2021 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is pleased...

OCEL : 2.6150 (-18.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 4.0127
2nd Resistance Point 3.5913
1st Resistance Point 3.1032
Last Price 2.6150
1st Support Level 2.1937
2nd Support Level 1.7723
3rd Support Level 1.2842

See More

52-Week High 4.8000
Fibonacci 61.8% 3.3087
Fibonacci 50% 2.8480
Last Price 2.6150
Fibonacci 38.2% 2.3873
52-Week Low 0.8960

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar